Evidence map›Paper›PMID 31599067›Full record

ArticleMolecular nutrition & food research2019

Mastiha (Pistacia lentiscus) Improves Gut Microbiota Diversity, Hepatic Steatosis, and Disease Activity in a Biopsy-Confirmed Mouse Model of Advanced Non-Alcoholic Steatohepatitis and Fibrosis.

Aimo Kannt, Efstathia Papada, Claire Kammermeier, Giuseppe D'Auria, Nuria Jiménez-Hernández, Martin Stephan, Uwe Schwahn, Andreas Nygaard Madsen, Mette Viberg Østergaard, George Dedoussis and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular nutrition & food research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Dual RNA sequencing ofmSystems · 2024
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Aimo KanntSanofi Research and Development, 65926, Frankfurt, Germany.ORCID 0000-0002-5197-2286
Efstathia PapadaHarokopio University Athens, Kallithea, 17676, Greece.
Claire KammermeierSanofi Research and Development, 65926, Frankfurt, Germany.
Giuseppe D'AuriaFoundation for the Promotion of Health and Biomedical Research (FISABIO), 46035, Valencia, Spain.
Nuria Jiménez-HernándezFoundation for the Promotion of Health and Biomedical Research (FISABIO), 46035, Valencia, Spain.
Martin StephanSanofi Research and Development, 65926, Frankfurt, Germany.
Uwe SchwahnSanofi Research and Development, 65926, Frankfurt, Germany.
Andreas Nygaard MadsenGubra, 2970, Horsholm, Denmark.
Mette Viberg ØstergaardGubra, 2970, Horsholm, Denmark.
George DedoussisHarokopio University Athens, Kallithea, 17676, Greece.
M Pilar FrancinoFoundation for the Promotion of Health and Biomedical Research (FISABIO), 46035, Valencia, Spain.
MAST4HEALTH consortium
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESSanofi (Germany) · DEGubra (Denmark) · DKHarokopio University of Athens · GRHeidelberg University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

scopeAs a result of the obesity epidemic, the prevalence of non-alcoholic steatohepatitis (NASH) is increasing. No drug is approved for the treatment of NASH. In this study, the effect of a nutritional supplement, Mastiha or Chios mastic gum, on metabolic and histological parameters and on the gut microbiome in mice with NASH and fibrosis was investigated. METHODS AND

resultsAdvanced NASH was induced by feeding C57BL/6J mice a diet rich in fat, sucrose, and cholesterol for 41 weeks. After randomization, animals received the NASH-inducing diet with or without 0.2% (w/w) Mastiha for a further 8 weeks. Disease activity was assessed by liver histology and determination of plasma transaminase activities. Fecal microbiota DNA extraction and 16S rRNA amplicon sequencing were used to determine the composition of the gut microbiome. Mastiha supplementation led to a significant reduction in circulating alanine aminotransferase (ALT) activity, improvement in hepatic steatosis and collagen content, and a reduction in NAFLD activity score. Furthermore, it resulted in a partial but significant recovery of gut microbiota diversity and changes in identity and abundance of specific taxa.

conclusionThis is the first study demonstrating an improvement in disease activity in mice with advanced NASH with fibrosis by a diet containing Mastiha.

Indexed as

Gastrointestinal MicrobiomePistaciaAnimalsBiopsyBody CompositionDiet, High-FatDisease Models, AnimalEatingFecesGene Expression RegulationLiver CirrhosisMaleMice, Inbred C57BLNon-alcoholic Fatty Liver DiseaseChios mastic gumfibrosisgut microbiomeMastihaNASHnon-alcoholic steatohepatitis

Identifiers

PMID31599067
PMCPMC7003480
OpenAlexW2979558277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.